Oncology

Inhibiting GCN5 enzyme may lead to reduced remission risks and improved cure rates.

While PSA levels decreased in patients, overall survival did not improve in patients with non-metastatic prostate cancer.

New system could lead to advances in cancer investigation and drug discovery.

Venetoclax (Venclexta)is the first treatment approved by the FDA that inhibits the B-cell lymphoma 2 (BCL-2) protein.

A flood of new therapies approved last year offer new hope for patients with multiple myeloma.

New technique allows physicians to see if a tumor is susceptible or resistant to treatment much earlier than conventional methods.

Atezolizumab treats locally advanced or metastatic NSCLC expressing the PD-L1 protein.

Top news of the day across the health care landscape.

Atezolizumab was previously granted Breakthrough Therapy Designation for NSCLC in February 2015.

Recent advances and updates in oncology and cancer drug development.

Experimental drug could may lead to new treatments for AML, lung cancer, brain cancer, and melanoma.

Only 20% of lung cancer patients show a response to current immunotherapeutic antibodies.

Study finds that manufacturers need to develop a new approach to engaging oncologists.

Top stories of the day from across the health care landscape.

SAMMSON gene thought to play an important role in the etiology of melanoma.

Combining drug trametinib with a superagonist can stimulate activity while preserving the cancer-blocking effects of the treatment.

Plant produces compounds that treat cancer, arrhythmia, and other medical problems.

HDAC inhibitors in combination with immune-stimulating agents improve tumor response.

New technique could soon move to clinical trials in prostate cancer.

Individualized approach allows for creation of widespread models of patient-specific tumors.

DNA screening technology up to 10,000 times more sensitive than current tests for cancer and HIV.

Human epidermal growth factor receptor linked to success of chemotherapy.

Bright white light therapy shows treats depressive symptoms in cancer patients.

Clinical benefit of 3 to 8 months found in some patients who received drugs that targeted tumors in the P13K/AKT/mTOR pathway.

Sulforaphane, which occurs naturally in several cruciferous vegetables, can change the activity of endogenous enzymes.

Recurrence Score test may help some women with breast cancer be spared of chemotherapy without experiencing disease progression.

Chronic CIPN is a common side effect of chemotherapy that appears a month after treatment for cancer.

Recent advances and updates in oncology and cancer drug development.